Evidence map›Paper›PMID 39511126›Full record

ArticleTargeted oncology2025

Optimal Duration of Consolidation Durvalumab Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer: A Multi-institutional Retrospective Study.

Hiroshi Doi, Yukinori Matsuo, Noriko Kishi, Masakazu Ogura, Takamasa Mitsuyoshi, Nami Ueki, Kazuhito Ueki, Kota Fujii, Masato Sakamoto, Tomoko Atsuta and 8 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Targeted oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Hiroshi DoiDepartment of Radiation Oncology, Faculty of Medicine, Kindai University, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka, 589-8511, Japan.
Yukinori MatsuoDepartment of Radiation Oncology, Faculty of Medicine, Kindai University, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka, 589-8511, Japan. ymatsuo@med.kindai.ac.jp.ORCID http://orcid.org/0000-0002-4372-8259
Noriko KishiDepartment of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Masakazu OguraDepartment of Radiation Oncology, Kishiwada City Hospital, Kishiwada, Japan.
Takamasa MitsuyoshiDepartment of Radiation Oncology, Kobe City Medical Center General Hospital, Kobe, Japan.
Nami UekiDepartment of Radiation Oncology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan.
Kazuhito UekiDepartment of Radiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Kota FujiiDepartment of Radiation Oncology, Kurashiki Central Hospital, Kurashiki, Japan.
Masato SakamotoDepartment of Radiation Oncology, Osaka Red Cross Hospital, Osaka, Japan.
Tomoko AtsutaDepartment of Radiation Oncology, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan.
Tomohiro KatagiriDepartment of Radiation Oncology, Tenri Hospital, Tenri, Japan.
Takashi SakamotoDepartment of Radiation Oncology, Kyoto Katsura Hospital, Kyoto, Japan.
Masaru NarabayashiDepartment of Radiology, Japanese Red Cross Fukui Hospital, Fukui, Japan.
Shuji OhtsuDepartment of Radiation Oncology, Kyoto City Hospital, Kyoto, Japan.
Satsuki FujishiroDepartment of Radiation Oncology, Shinko Hospital, Kobe, Japan.
Takahiro KishiDepartment of Radiation Oncology, Shizuoka City Shizuoka Hospital, Shizuoka, Japan.
Takashi MizowakiDepartment of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kyoto Radiation Oncology Study Group (KROSG)

Funding

Japan Society for the Promotion of Science 22K07733Japan Society for the Promotion of Science 24K10796
6 · The paper itself

Abstract

backgroundAlthough durvalumab has shown promise in improving survival rates in patients with locally advanced non-small cell lung cancer (NSCLC), the ideal duration of treatment has yet to be established.

objectiveThe primary objective of this study was to determine the optimal number of durvalumab cycles following definitive chemoradiotherapy for locally advanced NSCLC. PATIENTS AND

methodsA total of 178 patients who received chemoradiotherapy for stage III NSCLC at 15 institutions were retrospectively analyzed. Progression-free survival (PFS) and overall survival (OS) were assessed according to the number of consolidation durvalumab cycles by landmark analysis. Landmark analyses were performed at 3-month intervals from the start of durvalumab treatment to 9 months.

resultsThe median number of durvalumab cycles was 16 (range 1-27). PFS and OS were significantly better in patients who received ≥20 cycles of durvalumab than in those who did not (p < 0.001 and p < 0.001, respectively). In landmark analysis, significant differences were observed in PFS from 0 to 6 months and OS from 3 to 6 months between patients who continued durvalumab after the time point and those who did not. However, there were no significant differences in PFS or OS between patients who received 13-19 or ≥20 cycles of durvalumab at 9 months.

conclusionsDurvalumab should be administered for more than 6 months to contribute to the main benefits of consolidation therapy following chemoradiotherapy.

Indexed as

Antibodies, MonoclonalAntineoplastic Agents, ImmunologicalCarcinoma, Non-Small-Cell LungChemoradiotherapyLung NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm StagingRetrospective StudiesAntibodies, MonoclonalAntineoplastic Agents, Immunologicaldurvalumab

Identifiers

PMID39511126

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.